Establishment Labs Holdings Inc.

NASDAQ•ESTA

CEO: Mr. Juan Jose Chacon Quiros

Sector: Healthcare

Industry: Medical - Devices

Listing Date: 2018-07-19

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

Contact Information

Building B15 and 25, Coyol Free Zone, Alajuela, Costa Rica

506-2434-2400

www.establishmentlabs.com

Market Cap

$1.97B

P/E (TTM)

-38.9

23.8

Dividend Yield

52W High

$83.31

52W Low

$28.67

52W Range

70%

Rank59Top 87.6%

2.2

F-Score

Modified Piotroski Analysis

Based on 9-year fundamentals

Weak • 2.2 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2017-2025

Financial Dashboard

Q4 2025 Data

Revenue

$64.62M+0.00%

4-Quarter Trend

EPS

-$0.09+0.00%

4-Quarter Trend

FCF

-$2.43M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Revenue Growth Post-Approval Revenue reached $211.1M USD, increasing 27.2% driven by US market penetration post-approval.

US Market Sales Surge US market sales reached $45.6M USD for the year, following September 2024 FDA approval.

Gross Margin Improvement Gross margin increased to 69.3% from 66.0% due to higher selling prices in the United States.

Net Loss Significantly Narrows Net loss significantly narrowed to $51.1M USD, an improvement from the $84.6M USD loss reported previously.

Risk Factors

Sole Silicone Supplier Risk Reliance on sole silicone supplier Avantor presents risk as they plan to not automatically renew the supply agreement.

Continued Operating Losses Company incurred losses to date; achieving profitability depends on Motiva Implants commercial success and scaling.

Rising Operating Expenses Operating expenses rose significantly, with SG&A increasing 18.1% to $165.1M USD, impacting cost control.

Implant Safety Scrutiny Negative publicity and safety concerns regarding breast implants could harm reputation and reduce overall market demand.

Outlook

Preservé US Market Expansion Preservé launch continues through 2025, targeting a full commercial launch in the United States expected in 2026.

Elevated R&D Spending R&D expenses remain elevated for the decade-long post-approval study and advancing new product pipeline initiatives.

New CEO Strategy Execution New CEO appointed in May 2025; focus remains on executing US strategy and long-term growth priorities.

Future Capital Requirements Future capital needs depend on market adoption rates and managing significant ongoing regulatory compliance costs.

Peer Comparison

Revenue (TTM)

AHCO

$2.84B

+7.4%

TDOC

$2.53B

-1.5%

IART

$1.64B

+1.5%

Gross Margin (Latest Quarter)

IMTX

100.0%

+0.0pp

ATAI

100.0%

+0.0pp

TSHA

94.5%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
SYRE	$4.41B	-162.8	-29.4%	0.0%
NEOG	$2.07B	-3.4	-29.0%	0.0%
ZYME	$2.07B	-25.8	-26.0%	5.3%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

16.0%

Strong Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 5, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data